DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02908087

CompletedPhase 2

Incretin-based Therapy in Early Diagnosed Type 1 Diabetes

Lead sponsor

University of Oulu

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

4

Recruiting sites

—

Enrollment

13

actual

Study population

Type 1 diabetes

Key I/E criterion

—

Primary endpoint

•C-peptide AUC

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02908087
Org study IDLiraT1D10-30
Secondary ID2014-004760-37
Secondary IDU1111-1177-0661WHO

Timeline

Milestones

Study first posted2016-09-20estimated
Last update posted2022-01-11actual
Study start2016-03 (month precision)
Primary completion2021-05actual (month precision)
Study completion2021-05actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age10 Years
Maximum age30 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•10-30 years of age
•early diagnosis type 1 diabetes (no symptoms, diagnosis in OGTT)
•not pregnant.

Exclusion criteria

•allergic to liraglutide or other ingredients of Victoza®
•diabetic ketoacidosis
•previous treatment in the last three months with any antidiabetic medication other than insulin
•impaired liver or kidney function or on dialysis
•severe heart failure
•severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease
•past or current history of pancreatitis
•serum calcitonin value above normal (>50 ng/l or ≥3.4pmol/l)
•presence of any chronic metabolic, hematologic or malignant disease
•obesity BMI ≥30
•pregnant females and females of childbearing potential who are not using adequate contraceptive methods.
•breast-feeding

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
3
Glycemic / diabetes
2

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Serum C-peptide AUC

Time frame:From baseline to 26 and 52 weeks

C-peptide AUC

change from baseline, improvement

Secondary/protocol endpoint

Insulin dose

Time frame:From baseline to 26 and 52 weeks

change from baseline, improvement

Safety / tolerability / PK

3 endpoints
Secondary/protocol endpoint

Safety: Serum and urine amylase, serum lipase, serum calcitonin levels will be monitored

Time frame:From baseline to 26 and 52 weeks

descriptive

Secondary/protocol endpoint

Number of hypoglycemia episodes

Time frame:From baseline to 26 and 52 weeks

Documented hypoglycemia

event count, event

Secondary/protocol endpoint

Frequency of gastrointestinal side effects

Time frame:12 months

Diarrhea

event count, event

componentsDiarrhea, Nausea, Vomiting

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.